

# Kazuhiko Yoshida

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4231577/publications.pdf>

Version: 2024-02-01

91  
papers

1,317  
citations

430442

18  
h-index

454577

30  
g-index

92  
all docs

92  
docs citations

92  
times ranked

1712  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Impact of Trial-Eligibility Criteria in Patients with Metastatic Renal Cell Carcinoma. <i>Urologia Internationalis</i> , 2022, 106, 368-375.	0.6	6
2	Efficacy and feasibility of robot-assisted partial nephrectomy for octogenarians: comparison with younger counterparts. <i>Journal of Robotic Surgery</i> , 2022, 16, 1165-1173.	1.0	4
3	Comparison of surgical outcomes after robot-assisted laparoscopic partial nephrectomy between patients continuing and discontinuing aspirin therapy: a Japanese single-centre study. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	0.6	0
4	Thrombus-first or thrombus-last approach for surgical management of renal cell carcinoma with inferior vena cava thrombus. <i>International Journal of Urology</i> , 2022, , .	0.5	0
5	Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	0.6	0
6	New Longitudinal Component of the RENAL Nephrometry Score for Predicting the Operative Complexity in Transperitoneal Robot-Assisted Partial Nephrectomy. <i>Journal of Endourology</i> , 2022, 36, 762-769.	1.1	5
7	Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor Era. <i>Targeted Oncology</i> , 2022, 17, 307-319.	1.7	4
8	Perioperative outcomes following robot-assisted partial nephrectomy for renal cell carcinoma according to surgeon generation. <i>BMC Surgery</i> , 2022, 22, .	0.6	0
9	Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria. <i>Targeted Oncology</i> , 2022, 17, 475-482.	1.7	4
10	Comparisons of surgical outcomes between transperitoneal and retroperitoneal approaches in robot-assisted laparoscopic partial nephrectomy for lateral renal tumors: a propensity score-matched comparative analysis. <i>Journal of Robotic Surgery</i> , 2021, 15, 99-104.	1.0	20
11	Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 296-304.	0.6	4
12	Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 646-653.	0.6	22
13	Predictive role of $\gamma$ -glutamyltransferase in patients receiving nivolumab therapy for metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2021, 26, 552-561.	1.0	7
14	Efficacy of nivolumab versus molecular-targeted therapy as second-line therapy for metastatic renal cell carcinoma: Real-world data from two Japanese institutions. <i>International Journal of Urology</i> , 2021, 28, 99-106.	0.5	4
15	Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 793-801.	0.6	7
16	The Controlling Nutritional Status CONUT Score in Patients With Advanced Bladder Cancer After Radical Cystectomy. <i>In Vivo</i> , 2021, 35, 999-1006.	0.6	11
17	Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma. <i>Clinical and Experimental Nephrology</i> , 2021, 25, 674-682.	0.7	2
18	Early dark cortical band sign on CT for differentiating clear cell renal cell carcinoma from fat poor angiomyolipoma and detecting peritumoral pseudocapsule. <i>European Radiology</i> , 2021, 31, 5990-5997.	2.3	4

#	ARTICLE	IF	CITATIONS
19	Impact of sarcopenia on post-operative outcomes following nephrectomy and tumor thrombectomy for renal cell carcinoma with inferior vena cava thrombus. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 819-825.	0.6	11
20	Greater Renal Function Benefit from Enucleation Technique for More Complex Renal Tumors in Robot-Assisted Partial Nephrectomy. <i>Journal of Endourology</i> , 2021, 35, 1512-1519.	1.1	4
21	Prognostic Impact of Early Treatment Interruption of Nivolumab Plus Ipilimumab Due to Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma: A Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2021, 16, 493-502.	1.7	6
22	Comparison of Surgical Outcomes Between Enucleation and Standard Resection in Robot-Assisted Partial Nephrectomy for Completely Endophytic Renal Tumors Through a 1:1 Propensity Score-Matched Analysis. <i>Journal of Endourology</i> , 2021, 35, 1779-1784.	1.1	9
23	Tumor response in primary kidney lesions and metastatic lesions in nivolumab plus ipilimumab therapy for advanced renal cell carcinoma without prior nephrectomy: Preliminary results of a multi-institutional study. <i>International Journal of Urology</i> , 2021, 28, 1075-1076.	0.5	3
24	Limited impact of warm ischemic threshold for partial nephrectomy in the robotic surgery era: A propensity score matching study. <i>International Journal of Urology</i> , 2021, 28, 1219-1225.	0.5	4
25	Association of tumor burden with outcome in first-line therapy with nivolumab plus ipilimumab for previously untreated metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1751-1756.	0.6	7
26	Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. <i>Pathology</i> , 2021, 53, 720-727.	0.3	8
27	Prognostic impact of immune-related adverse events in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 735.e9-735.e16.	0.8	15
28	Detection of a peritumoral pseudocapsule in patients with renal cell carcinoma undergoing robot-assisted partial nephrectomy using enhanced MDCT. <i>Scientific Reports</i> , 2021, 11, 2245.	1.6	7
29	Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2021, 35, 3585-3589.	0.6	4
30	Predictive impact of early changes in serum C-reactive protein levels in nivolumab plus ipilimumab therapy for metastatic renal cell carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, , .	0.9	6
31	Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 705-712.	1.0	3
32	The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 236-240.e1.	0.9	12
33	Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 526-532.	0.8	18
34	Genetic and epigenetic profiling indicates the proximal tubule origin of renal cancers in end-stage renal disease. <i>Cancer Science</i> , 2020, 111, 4276-4287.	1.7	11
35	Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2020, 34, 1541-1546.	0.6	10
36	Lower Incidence of Postoperative Acute Kidney Injury in Robot-Assisted Partial Nephrectomy Than in Open Partial Nephrectomy: A Propensity Score-Matched Study. <i>Journal of Endourology</i> , 2020, 34, 754-762.	1.1	13

#	ARTICLE	IF	CITATIONS
37	Clinical outcomes of repeat partial nephrectomy compared to initial partial nephrectomy of a solitary kidney. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1155-1162.	1.0	10
38	Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 933-939.	0.6	21
39	Mid-term outcome of transarterial embolization of renal artery pseudoaneurysm and arteriovenous fistula after partial nephrectomy screened by early postoperative contrast-enhanced CT. <i>CVIR Endovascular</i> , 2020, 3, 68.	0.4	4
40	Computed tomography imaging characteristics of clear cell papillary renal cell carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2020, 46, 26-33.	0.7	6
41	Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2019, 14, 453-463.	1.7	53
42	Negative Effect of Immediate Sunitinib Interruption on Survival in Patients With Metastatic Renal Cell Carcinoma. <i>In Vivo</i> , 2019, 33, 2153-2160.	0.6	6
43	Association between tumor contact surface area and parenchymal volume change in robot-assisted laparoscopic partial nephrectomy carried out using the enucleation technique. <i>International Journal of Urology</i> , 2019, 26, 745-751.	0.5	5
44	Spatial and temporal responses of metastatic renal cell carcinoma lesions to sequential treatments over a 10-year period. <i>IJU Case Reports</i> , 2019, 2, 37-42.	0.1	0
45	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2019, 36, 35.	1.2	4
46	Efficacy of axitinib in patients with metastatic renal cell carcinoma refractory to nivolumab therapy. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 576-580.	0.6	11
47	Prognostic Markers for Refined Stratification of IMDC Intermediate-Risk Metastatic Clear Cell Renal Cell Carcinoma Treated with First-Line Tyrosine Kinase Inhibitor Therapy. <i>Targeted Oncology</i> , 2019, 14, 179-186.	1.7	14
48	Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 355.e21-355.e29.	0.8	64
49	Assessment of postoperative renal function after adrenalectomy in patients with primary aldosteronism. <i>International Journal of Urology</i> , 2019, 26, 229-233.	0.5	16
50	Peritumoral pseudocapsule status according to pathological characteristics from robot-assisted laparoscopic partial nephrectomy for localized renal cell carcinoma. <i>International Journal of Urology</i> , 2019, 26, 446-450.	0.5	13
51	Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy. <i>International Journal of Clinical Oncology</i> , 2018, 23, 559-567.	1.0	11
52	Prognostic value of the Glasgow Prognostic Score for patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy. <i>International Journal of Clinical Oncology</i> , 2018, 23, 539-546.	1.0	13
53	Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2018, 35, 78.	1.2	15
54	Comparison of Kidney Function in the Early Postoperative Period in Transperitoneal Robot-Assisted Laparoscopic Partial Nephrectomy Between Anterior and Posterior Renal Tumors: A Propensity Score-Matched Study. <i>Journal of Endourology</i> , 2018, 32, 111-115.	1.1	10

#	ARTICLE	IF	CITATIONS
55	Immediate Progressive Disease in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab: a Multi-Institution Retrospective Study. <i>Targeted Oncology</i> , 2018, 13, 611-619.	1.7	3
56	Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 745-755.	1.7	14
57	Acquired cystic disease-associated renal cell carcinoma is the most common subtype in long-term dialyzed patients: Central pathology results according to the 2016 WHO classification in a multi-institutional study. <i>Pathology International</i> , 2018, 68, 543-549.	0.6	37
58	Prognostic Impact of the Components of Progressive Disease on Survival After First-Line Tyrosine Kinase Inhibitor Therapy for Metastatic Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2018, 13, 379-387.	1.7	4
59	Durable response after discontinuation of nivolumab therapy in patients with metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 860-863.	0.6	14
60	Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 667-672.	0.6	12
61	Evaluation of tumor burden after sequential molecular-targeted therapy in patients with metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 226-232.	0.6	8
62	Preoperative controlling nutritional status (CONUT) score as a novel predictive biomarker of survival in patients with localized urothelial carcinoma of the upper urinary tract treated with radical nephroureterectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 539.e9-539.e16.	0.8	41
63	Robot-assisted laparoscopic versus open partial nephrectomy in patients with chronic kidney disease: A propensity score-matched comparative analysis of surgical outcomes. <i>International Journal of Urology</i> , 2017, 24, 505-510.	0.5	24
64	Incidental detection of asymptomatic migration of Hemoclock clip into the bladder after laparoscopic radical prostatectomy. <i>Asian Journal of Endoscopic Surgery</i> , 2017, 10, 442-445.	0.4	7
65	Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 598-604.	0.9	27
66	Comparison of Surgical Outcomes Between Resection and Enucleation in Robot-Assisted Laparoscopic Partial Nephrectomy for Renal Tumors According to the Surface-Intermediate-Base Margin Score: A Propensity Score-Matched Study. <i>Journal of Endourology</i> , 2017, 31, 756-761.	1.1	20
67	Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 495-501.	0.9	22
68	Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 542.e1-542.e9.	0.8	21
69	Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer. <i>International Journal of Clinical Oncology</i> , 2017, 22, 145-152.	1.0	13
70	Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 1175-1181.	0.6	17
71	Comparison of progression to end-stage renal disease requiring dialysis after partial or radical nephrectomy for renal cell carcinoma in patients with severe chronic kidney disease. <i>International Urology and Nephrology</i> , 2016, 48, 1421-1427.	0.6	15
72	Comparison of survival rates in stage 1 renal cell carcinoma between partial nephrectomy and radical nephrectomy patients according to age distribution: a propensity score matching study. <i>BJU International</i> , 2016, 117, E52-9.	1.3	13

#	ARTICLE	IF	CITATIONS
73	A propensity score-matched comparison of surgical precision obtained by using volumetric analysis between robot-assisted laparoscopic and open partial nephrectomy for T1 renal cell carcinoma: a retrospective non-randomized observational study of initial outcomes. <i>International Urology and Nephrology</i> , 2016, 48, 1585-1591.	0.6	17
74	Aldo-keto reductase 1C1 induced by interleukin-1 $\beta$ mediates the invasive potential and drug resistance of metastatic bladder cancer cells. <i>Scientific Reports</i> , 2016, 6, 34625.	1.6	58
75	Early unclamping might reduce the risk of renal artery pseudoaneurysm after robot-assisted laparoscopic partial nephrectomy. <i>International Journal of Urology</i> , 2015, 22, 1096-1102.	0.5	54
76	Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1035-1041.	1.0	18
77	Renal sinus exposure as an independent factor predicting asymptomatic unruptured pseudoaneurysm formation detected in the early postoperative period after minimally invasive partial nephrectomy. <i>International Journal of Urology</i> , 2015, 22, 356-361.	0.5	33
78	Assessment of Surgical Outcomes of the Non-renorrhaphy Technique in Open Partial Nephrectomy for T1b Renal Tumors. <i>Urology</i> , 2015, 86, 529-533.	0.5	23
79	Possible Role of Template-based Lymphadenectomy in Reducing the Risk of Regional Node Recurrence after Nephroureterectomy in Patients with Renal Pelvic Cancer. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 1233-1238.	0.6	21
80	<sc>IJU</sc> this issue. <i>International Journal of Urology</i> , 2014, 21, 441-441.	0.5	24
81	Better recovery of kidney function in patients with de novo chronic kidney disease after partial nephrectomy compared with those with pre-existing chronic kidney disease. <i>International Journal of Urology</i> , 2014, 21, 613-616.	0.5	8
82	Cystic local recurrence of renal cell carcinoma after laparoscopic radical nephrectomy in a hemodialysis patient. <i>International Journal of Urology</i> , 2014, 21, 330-332.	0.5	1
83	Template-based lymphadenectomy in urothelial carcinoma of the renal pelvis: A prospective study. <i>International Journal of Urology</i> , 2014, 21, 453-459.	0.5	48
84	Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma-Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 270-277.	0.6	83
85	Successful Kidney Transplantation for End-Stage Renal Disease in Marfan's Syndrome. <i>Case Reports in Transplantation</i> , 2013, 2013, 1-4.	0.1	0
86	Negative impact of papillary histological subtype in patients with renal cell carcinoma extending into the inferior vena cava: Single-center experience. <i>International Journal of Urology</i> , 2013, 20, 1072-1077.	0.5	19
87	Clinical Results and Pharmacokinetics of Sorafenib in Chronic Hemodialysis Patients with Metastatic Renal Cell Carcinoma in a Single Center. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 647-655.	0.6	40
88	Nifedipine enhances cGMP production through the activation of soluble guanylyl cyclase in rat ventricular papillary muscle. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 511-514.	1.2	5
89	A case of primary renal angiosarcoma. <i>Rare Tumors</i> , 2009, 1, 85-87.	0.3	17
90	Anti-Granular Basement Membrane Antibody Disease with Granulomatous Lesions on Renal Biopsy. <i>Internal Medicine</i> , 2007, 46, 295-301.	0.3	1

#	ARTICLE	IF	CITATIONS
91	Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Japanese Journal of Clinical Oncology, 0, , .	0.6	1